Navigation Links
Catalent Completes Purchase of Pharmaceutical Packaging Facility in Shiga, Japan
Date:7/1/2020

Catalent, a global leader in clinical supply services, today announced that it had completed the purchase of Teva-Takeda Pharmaceuticals’ packaging facility in Minakuchi, located in the Shiga prefecture of Japan.

Operating in partnership with the company’s existing Japanese clinical supply facility located in Kakegawa, the new 60,000-square-foot facility will provide customers with flexible clinical supply solutions, serving both local customers, and global biotech and pharmaceutical companies. The facility will play an important role in Catalent’s expanding Asia-Pacific network, working alongside two sites in China and one in Singapore to ensure customers’ clinical trials are well-served across the region.

The facility will offer extensive clinical supply services including access to Catalent’s FastChain® demand-led supply services, primary and secondary packaging capabilities, a range of temperature options for storage and distribution, as well as clinical returns and destruction services.

For more information on Catalent’s clinical supply capabilities visit https://www.clinical.catalent.com.

About Catalent Clinical Supply Services
Catalent is a global leader in clinical supply services, with comprehensive and flexible solutions for small molecules, biologics, and cell and gene therapies and integrated solutions to accelerate speed to clinic. Catalent offers a full range services including clinical supply management, comprehensive packaging solutions, comparator sourcing, cold chain storage and global distribution and specialized supply chain services including direct-to-patient and demand-led supply. With nine GMP clinical packaging facilities and over 50 strategically located depots on six continents combined with more than 25 years’ experience across thousands of studies in more than 80 countries, Catalent has the comprehensive services, global scale and expertise necessary to reliably supply clinical trials of all sizes and complexity anywhere in the world.

About Catalent
Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs over 13,500 people, including approximately 2,400 scientists and technicians, at more than 40 facilities, and in fiscal year 2019 generated over $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com

More products. Better treatments. Reliably supplied.™

Read the full story at https://www.prweb.com/releases/catalent_completes_purchase_of_pharmaceutical_packaging_facility_in_shiga_japan/prweb17231096.htm.


'/>"/>
Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved


Related biology news :

1. Catalent to Present Assessment Methods and Design Approaches for T-Cell Manufacturing Challenges at ISCT 2020 Virtual
2. Catalent to Partner with Ethicann on New Fast-Dissolve Cannabinoid-Based Treatment for Multiple Sclerosis Spasticity
3. Catalent to Discuss the Future of Cell and Gene Therapy Manufacturing at World Orphan Drug Congress Europe
4. Catalent to Present Case Studies on Formulation Design for Early Phase Molecules and Discuss Benefits of Mass Spectrometry for HCP Analysis at AAPS PharmSci 360
5. Catalent Announces the Appointment of David Schaffer to Biologics Advisory Board
6. Catalent to Launch OneBio Suite for Integrated Biologics Development, Manufacturing and Supply at BIO International 2019
7. Planning for Orphan Drug Supply to be Discussed by Catalent at World Orphan Drug Congress
8. Catalent Receives P&G External Business Partner of the Year Award
9. Lifecycle Biotechnologies Completes Full Integration of Chata Biosystems and VI Plastics
10. Great Point Partners Completes Growth Equity Investment in Axiom Real-Time Metrics
11. Bode Technology Completes DNA Analysis on 100,000 Sexual Assault Kits
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2020)... ... , ... Accumen Inc. is helping healthcare get better, faster. ... to provide COVID-19 saliva testing kits nationally. , “Accumen has been partnering ... years. Early in the COVID-19 crisis, we identified supply chain gaps and began ...
(Date:7/18/2020)... , ... July 16, 2020 , ... ... demonstrates the effectiveness of the Invictus Medical Neoasis™ active noise control device to ... study reported that the Neoasis™ device attenuated the alarm sounds from patient monitors, ...
(Date:7/4/2020)... PHOENIX (PRWEB) , ... July 03, 2020 , ... ... is proud to earn outstanding recognition and multiple awards for not only the ... the ABM portfolio, SoME® Skincare and Vivace® Microneedle RF. All the brands built ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... ... July 29, 2020 , ... eSource has long been touted as ... cover the history of eSource, the reasons it did not take off as quickly ... site source, the industry is moving towards capturing data electronically for clinical trials and ...
(Date:7/18/2020)... ... July 16, 2020 , ... After research model surgery and ... a great surgery is only the beginning of a successful study, while protecting and ... Join Brad Gien, Global Head of Surgery from Envigo in a ...
(Date:7/10/2020)... ... July 08, 2020 , ... Bode ... significant expansion of laboratory operations through its COVID-19 testing service, Bode-CARES . ... , Bode-CARES provides a turnkey solution that includes a comprehensive ...
(Date:7/7/2020)... ... July 06, 2020 , ... R3 International is now offering stem cell therapy ... stem cells. Depending on the patient's condition, treatment may be offered IV, intrathecal or ... some form of Alzheimers dementia, and the incidence continues to increase as individuals live ...
Breaking Biology Technology: